Akero ex­ec­u­tives point to ad­vanced fi­bro­sis pa­tients for MASH drug

Akero Ther­a­peu­tics ex­pects its promis­ing ex­per­i­men­tal MASH drug will be used to treat pa­tients with ad­vanced fi­bro­sis if it re­ceives FDA ap­proval, liken­ing MASH to the dense di­a­betes mar­ket.

Ear­li­er this week, Akero shared mid-stage da­ta that showed its meta­bol­ic dys­func­tion-as­so­ci­at­ed steato­hep­ati­tis (MASH) drug helped im­prove fi­bro­sis. The read­out sent its stock soar­ing on Mon­day, and Akero then an­nounced plans to raise $319 mil­lion in a pub­lic of­fer­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER